氨己烯酸片(喜保宁)的效果怎么样

The trade name of Vigabatrin is Sabril. It was approved for marketing in the United States in August 2009. It is available in tablets and oral solutions and is used to treat epilepsy in infants and adults. The successful development of vigabatrin tablets (Vigabatrin) has given many patients new hope for treatment.

The global average incidence of epilepsy is about 0.6%, one-third of which are refractory to treatment. Vigabatrin is the FDA's first drug to treat infantile spasms. In the past two years, more and more children with TSC have effectively controlled epilepsy through the use of Vigabatrin, especially for infantile spasms. Western countries even use vigabatrin tablets to prevent children with TSC who have not yet developed the disease once they develop brain electrical abnormalities.

Clinical trials have shown that vigabatrin tablets (Vigabatrin) have significant therapeutic effects, but taking this drug for treatment will also produce certain side effects or adverse reactions. Common ones include: fatigue/drowsiness/headache/dizziness/mental confusion/depression, etc. Before receiving treatment with vigabatrin tablets (Vigabatrin), patients should go to the hospital for a detailed examination and strictly take medication according to the doctor's diagnosis and treatment recommendations. The use of vigabatrin tablets (Vigabatrin) should be carried out under the guidance of an epilepsy expert or a child neurologist. Reactions after taking the medication should be reported to the doctor promptly.

Dosage for the elderly and patients with renal impairment: Because Vigabatrin is digested by the kidneys, caution should be exercised when the elderly and patients with a creatinine elimination rate less than 60 ml/min (60 ml per minute) take this drug. For both groups, reductions in dosage and frequency should be considered. A small amount of medication may be effective for both types of people. Such patients should be monitored for signs of unusual sedation or confusion.

Vigabatrin is not recommended for patients with pre-existing significant visual field defects. Patients should undergo system scans when starting Vigabatrin and at regular intervals for visual field defects. Visual field examinations should be performed every six months throughout treatment.

If visual field constriction is observed during the follow-up period, consideration should be given to gradually discontinuing Vigabatrin. If the decision is made to continue treatment with Vigabatrin, more frequent follow-up visual examinations should be performed to determine disease progression or threat of visual field loss.

Recommended related hot articles: /newsDetail/84696.html